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Procoagulant effect of the OKT3 monoclonal antibody: Involvement of
tumor necrosis factor. We recently observed that the prophylactic
administration of high doses of OKT3 monoclonal antibody (MoAb) in
cadaveric renal transplantation favors the development of thromboses
of the grafts' main vessels and of thrombotic microangiopathies. These
clinical observations led us to perform sequential determinations of
plasma levels of prothrombin fragment 1 and 2 (F 1 + 2) and fibrin
degradation products (FDP) after the first injection of 5 or 10 mg OKT3
given as prophylaxis in kidney transplant recipients. The values ob-
served have been compared with those of kidney transplant recipients
not treated with OKT3. F I + 2 levels peaked four hours after the first
injection of 5 mg OKT3 (mean SEM: 4.82 0.73 vs. 1.75 0.37
nmollliter in controls, P < 0.01), indicating activation of the common
pathway of the coagulation cascade. FDP levels were already above
baseline values at four hours and continued to increase until 24 hours
(mean SEM at 24 hr, 4729 879 vs. 1038 320 nglml in controls, P
<0.05), indicating a fibrinolytic process. The magnitude and the time
course of the changes in F I + 2 and FDP plasma levels were similar
whether the patients received 5 or 10 mg dose of OKT3. The levels of
von Willebrand factor (VWF) antigen, a molecule released by activated
or damaged endothelial cells, were also significantly increased after
injection of OKT3 (mean SEM at 24 hr, 3.67 0.18 vs. 2.17 0.11
U/mI in controls, P < 0.05). The procoagulant effects of OKT3 were
further investigated in vitro on human umbilical vein endothelial cells
(HUVEC). It was found that OKT3 induces peripheral blood mononu-
clear cells (PBMC) to release soluble mediators that trigger the gener-
ation of thrombin at the HUVEC surface by a tissue factor-dependent
mechanism. The addition of chimeric anti-TNF-s MoAb to culture
supernatants of OKT3-stimulated PBMC strongly inhibited the throm-
bin generation in this model. We conclude that OKT3 activates the
coagulation cascade in vivo and that TNF-a is a mediator of the
procoagulant effects of OKT3 at the endothelial cell level.
The first dose reactions observed after the administration of
the OKT3 monoclonal antibody (MoAb) in transplant recipients
include fever, chills, headaches and digestive symptoms El].
Occasionally, more severe complications such as pulmonary
edema and aseptic meningitis also occur. These adverse reac-
tions appear to be related to the systemic release of cytokines,
particularly of tumor necrosis factor-alpha (TN F-a) 12, 3]. We
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recently observed a new and severe complication of high-dose
prophylactic OKT3 (10 mg/day) in kidney transplant recipients,
namely the occurrence of intragraft thromboses [4]. In parallel,
we found that the first injection of such a high dose of OKT3 is
followed by a significant increase in the plasma levels of
prothrombin fragment 1 + 2 (F 1 + 2), indicating activation of
the common pathway of the coagulation system [4].
The present study was undertaken to further investigate the
effects of OKT3 on hemostatic processes. First, we performed
sequential determinations of plasma levels of F 1 + 2 and fibrin
degradation products (FDP) after injection of a conventional (5
mg) or high (10 mg) dose of OKT3 in kidney transplant
recipients. Second, we measured plasma levels of von Wille-
brand factor (VWF) antigen as a marker of endothelial cell
activation. Third, we developed an in vitro model allowing to
investigate the role of TNF-a in the procoagulant properties of
OKT3 at the endothelial cell level.
Methods
Patients
Adult recipients of cadaveric renal transplants were studied
immediately before and during the first four or 24 hours
post-transplantation. In the OKT3 groups, patients received an
i.v. injection of 5 mg (N = 10) or 10 mg (N = 7) OKT3
(Orthoclone, Ortho Biotech, Raritan, New Jersey, USA) at the
initiation of transplant surgery. Other immunosuppressive
agents on the day of transplantation included azathioprine 2
mg/kg, and methylprednisolone 8 mg/kg given as an i.v. bolus
three hours before surgery. In the control group, patients were
immunosuppressed with azathioprine and methylprednisolone
only during the first four hours (N = 4) or during the first 24
hours (N = 3) post-transplantation. As shown in Table 1, the
immunological characteristics and the ischemia times were
similar in the three groups of kidney transplant recipients.
In addition, we studied three patients who received a first
injection of 10 mg OKT3 during the first trimester posttrans-
plantation as anti-rejection therapy while they were under low
dose prednisolone (0.3 to 0.5 mg/kg) and azathioprine (1 to 2
mg/kg), together with (N = 1) or without (N = 2) cyclosporin A
(4 mg/kg). As in the prophylactic protocol, the OKT3 injection
was preceded by an i.v. bolus of methyiprednisolone (8 mg/kg).
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Table 1. Immunological parameters and ischemia times
Controls OKT3 5 mg OKT3 10 mg
(N = 7) (N = 10) (N = 7)
No. of recipients with
previous grafts
No. of recipients with
anti-HLA antibodies
HLA incompatibilities
0/7 1/10 1/7
2/7 3/10 1/7
DR
Ischemia times (hours)
Data are presented as mean sEM; differences between the groups
are not statistically significant.
Blood collection
Blood samples were collected through a central venous
catheter immediately before and 2, 4, 8 and 24 hours after the
first injection of OKT3. In control patients, blood sampling was
started at the initiation of surgery and followed the same timing
as in OKT3 patients, except that four patients of this group
could only be investigated during the first four hours because
they subsequently received OKT3. After discarding the first 20
ml, blood was collected into vacuum tubes containing CTAD or
tn-sodium citrate 3.8% as the anticoagulant (Diatube, Stago,
Terumo Europe, Leuven, Belgium). Samples were kept on ice,
centrifuged at 4000 rpm and plasma were stored at —70°C until
assayed.
Hemostatic assays on plasma samples
Commercially available ELISA kits were used for determi-
nation of F I + 2 (Behringwerke, Marburg, Germany), FDP
(Fibrinostika, Organon Teknika, Boxtel, Holland) [51and VWF
antigen (Stago, Franconville, France).
In vitro stimulation of peripheral blood mononuclear cells
with OKT3
Peripheral blood mononuclear cells were isolated from blood
obtained from healthy volunteers by Ficoll-Hypaque density
gradient centrifugation and cultured in 5% CO2 atmosphere in
M199 medium (Flow, Irvine, Scotland, UK) supplemented with
20% human serum, in the presence or absence of OKT3 10
ng/ml. Culture supernatants were collected after 24 hours and
stored at —70°C until used in the assays described below.
Generation of thro,nbin at the surface of human umbilical
vein endothelial cells
Human umbilical vein endothelial cells (HUVEC) isolated
according to the method of Jaff [6] were cultured using M199
medium supplemented with 20% human serum, essential amino
acids, endothelial cell growth factor (ECGF) (40 sg/ml), hepann
(100 g/ml), penicillin and streptomycin, Cells from the second
passage (2 io cells/ml) were transferred into 96 well plates and
used at confluence after 24 hours in the absence of heparin and
ECGF. After washing, 100 d culture supernatants of PBMC
were added, and the thrombin generated at the surface of
HUVEC was determined by addition of calcium (100 /Ll, 30 mM,
2 mm at 37°C) followed by normal human citrated plasma (45
sec at 37°C) before incubation with the chromogenic substrate
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Fig. 1. Evolution ofF I + 2plasma levels (mean SEM) after injection
of 5 mg prophylactic OKT3 in kidney transplant recipients (N = 10)and
in controls (N = 7 except for the 8 hr and 24 hr time points where N =
3). Symbols are: (•) OKT 5 mg; (0) controls; ** < 0.01.
(S2238, Kabi Vitrum, 0.7 m, 100 pi, 20 mm at 37°C). The
reaction was stopped with acetic acid (50 d) and the absorb-
ance red at 405 nm [7]. The amount of thrombin generated in
this system was calculated using a standard curve obtained with
purified thrombin and was expressed in mUnits of thrombin per
l0 HUVEC. In some experiments, supernatants of OKT3-
stimulated PBMC were incubated for two hours with different
amounts of chimeric (human-mouse) anti-human TNF-a MoAb
(provided by Centocor, Malvern, USA) or of an isotype-
matched MoAb before to be incubated with HUVEC.
Statistical analysis
Differences between groups were analyzed by Student's
Results
t-test.
In vivo activation of the common pathway of coagulation by
5 mg OKT3
We measured F 1 + 2 and FDP plasma levels after the first
injection of 5 mg OKT3 given prophylactically during transplan-
tation surgery. As shown in Figure 1, a major increase in F I +
2 levels, reflecting activation of the common coagulation path-
way, was observed at four hours (mean SEMat 4 hr, 4.82
0.73 vs. 1.75 0.37 nmol/liter in controls, P < 0.01).
F 1 + 2 plasma levels returned to basal values within 24 hours
except in two OKT3 patients. In one of them, thrombosis of the
graft vein became apparent on the second postoperative day
6-
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OKT3 dose
Peak plasma levels
F I + 2 nmol/!iter FDP ng/ml
5 mg (N = 10) 4.82 0.73 4729 879
10 mg (N = 7) 5.88 0.75 4422
while the other developed a thrombotic microangiopathy diag-
nosed on the fifth post-operative day. The increase in F 1 + 2
levels was only observed after the first injection of OKT3. No
significant changes were observed after the subsequent injec-
tions of the MoAb (data not shown).
As compared with controls, OKT3 patients also displayed
increased FDP levels, indicating the occurrence of a fibrinolytic
process (Fig. 2). This change was already apparent at four
hours, but was more pronounced at 24 hours (mean SEM, 4729
879 vs. 1038 320 ng/ml in controls, P < 0.05).
As shown in Table 2, the changes in hemostatic parameters
were essentially independent of the OKT3 dose. Peak plasma
levels of F 1 + 2 were slightly higher in the patients who
received 10 mg OKT3 but the difference did not reach statistical
significance (P = 0.411).
Activation of coagulation was also evident when OKT3 was
given as anti-rejection therapy. As shown in Figure 3, F 1 + 2
and FDP levels increased in the three patients studied with a
kinetic similar to that observed under prophylactic OKT3.
Increased plasma levels of von Willebrand factor after
injection of OKT3
As several cytokines released after the first injection of OKT3
might affect endothelial cells, we monitored plasma levels of
VWF antigen [61. Data represented in Figure 4 show that VWF
plasma levels rose significantly following the injection of 5 mg
prophylactic OKT3 (mean SEM at 24 hr, 3.67 0.18 vs. 2.17
0.11 U/mI in controls, P < 0.05).
OKT3 generates procoagulant activity at the surface of
HUVEC
We next investigated the ability of OKT3 to induce thrombin
generation at the surface of endothelial cells. For this purpose,
HUVEC were incubated with OKT3 or with supernatants of
PBMC stimulated by 10 nglml OKT3 before measurement of
thrombin activity. We first observed that culturing HUVEC
either with OKT3 alone (10 nglml) or with supernatants of
unstimulated PBMC did not result in significant thrombin
generation (Fig. 5). On the other hand, supernatants of OKT3-
stimulated PBMC induce a massive generation of thrombin at
the HUVEC surface. The magnitude and the time-course of this
process was similar to that induced by recombinant TNF-a (10
nglml). The same experiments were repeated using factor
Vu-deficient plasma. Under this condition, supernatants of
OKT3-stimulated PBMC did not induce any detectable throm-
bin generation, suggesting that this phenomenon was dependent
on tissue factor expression (data not shown).
TNF-a is a mediator of the procoagulant effect of OKT3 at
the endothelial cell level
Since supernatants of OKT3-stimulated PBMC contain high
levels of TNF-a and because of the well-known procoagulant
properties of this mediator, we investigated the role of TNF-a
in the effects of OKT3 on HUVEC. As shown in Figure 6, the
addition of a neutralizing chimeric anti-TNF-a MoAb to a
culture supernatant of OKT3-stimulated PBMC (containing 1.9
nglml TNF-a) resulted in a dose-dependent inhibition of the
thrombin generation. A 80% inhibition was achieved with I
g/ml chimeric anti-TNF-a MoAb whereas an isotype-matched
control MoAb at the same concentration had no effect.
Discussion
The first observation of this study is that the first dose of 5 mg
OKT3 in transplant recipients induces the activation of the
common pathway of coagulation, as indicated by a significant
rise in F 1 + 2 plasma level four hours after the injection of the
MoAb. F I + 2 fragment is released during conversion of
prothrombin to thrombin so that its measurement directly
reflects activation of prothrombin [8]. In addition, the increase
in FDP levels indicates that a fibrinolytic process also occurs
after injection of OKT3. Although parameters of primary fi-
brinolysis were not measured, the late increase in FDP levels
suggests that fibrinolysis after injection of OKT3 might, at least
in part, be secondary to activation of the coagulation cascade.
Since our first observations of thrombotic complications
consecutive to prophylactic OKT3 were made in patients re-
ceiving a high (10 mg) daily dose of the MoAb [4], we analyzed
the impact of OKT3 dosage on hemostatic parameters. F 1 + 2
and FDP peak levels were similar whether the patients received
the usual S mg dose or the high 10mg dose of OKT3. This is in
agreement with our most recent clinical data suggesting that, in
kidney transplant recipients, 5 mg OKT3 treatment also carries
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Fig. 2. FDP plasma levels (mean SEM) before, 4 hours and 24 hours
after injection of 5 mg prophylactic OKT3 in kidney transplant recipi-
ents (, N = 10) and in controls (D, N = 7except at 24 hr where N =
3). P < 0.05.
Table 2. Peak plasma levels of F I + 2 and FDP levels according to
OKT3 dosage
24
Time, hours
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Fig. 4. Plasma levels of VWF antigen (mean SEM) before, 4 hours
and 24 hours after injection of 5 mg prophylactic OKT3 in kidney
transplant recipients (D, N = 10) and in controls (, N = 7 except at
24 hr where N = 3). P < 0.05.
an increased risk of thrombotic complications, as illustrated in
two patients of the present study.
It is likely that cytokines released in the circulation after the
first injection of OKT3 play a central role in the procoagulant
effect of the MoAb, as previously suggested by Kanfer et al [9].
Thus, interferon-y has been shown to be involved in the
induction of monocyte procoagulant activity by OKT3 in vitro
[101. Moreover, TNF-a is known to promote fibrin deposition
and intravascular coagulation in vivo [11]. Interestingly, the
magnitude and the time course of the changes in F I + 2 plasma
levels in our patients were very similar to those reported by van
der Poll et al in healthy volunteers injected with recombinant
TNF-a [12]. In this setting, it is clear that the extrinsic route and
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Fig. 5. Thrombin generation (mean SEM of triplicate wells) at the
surface of HUVEC at various times after incubation either with
medium alone (V), with supernatants of unstimulated PBMC (E), with
supernatants of OKT3-stimulated PBMC (V), or with recombinant
TNF-a (10 ng/ml) (•).
not the contact system of coagulation was activated [12].
Endothelial cells could play an important role in this phenom-
enon since TNF-a stimulates the expression of tissue factor at
their surface [13].
Our previous clinicopathological observations of thrombotic
microangiopathy mimicking hemolytic-uremic syndrome as a
complication of prophylactic OKT3 already suggested that
endothelial cells are important targets of OKT3 toxicity [4]. The
twofold increase in VWF levels 24 hours after injection of
OKT3 is consistent with the hypothesis that endothelial cells
are activated and/or damaged as a consequence of the admin-
istration of the MoAb. In vitro experiments on HUVEC al-
lowed to determine more precisely the procoagulant effects of
OKT3 at the endothelial cell level. While the MoAb has no
direct effect on HUVEC, it induces PBMC to release soluble
factors which trigger thrombin generation at the HUVEC
surface by a tissue factor-dependent mechanism. The blocking
effect of a chimeric anti-TNF-a MoAb revealed that TNF-a is a
crucial mediator of the procoagulant effect of OKT3 in this
12
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system. This does not exclude the involvement of other cyto-
kines, that is, interferon-y, which are known to act in synergy
with TNF-a in the induction of endothelial cell changes [II].
As far as the clinical relevance of our findings is concerned,
one should first stress that the activation of coagulation is very
transient and is only observed after the first injection of the
MoAb. Interestingly, the release of cytokines also only occurs
after the first injection OKT3 [2, 3]. In fact, the changes in
hemostatic parameters parallel the release of cytokines which is
maximal two hours after the first OKT3 injection. Since the
main thrombotic complications in our experience occurred in
patients receiving prophylactic OKT3 and involved intragraft
vessels, it is possible that endothelial damages induced by
ischemia and/or surgery contribute to the development of
thromboses. Although thrombotic complications have not been
reported as yet in patients receiving OKT3 as anti-rejection
therapy, one should be aware that activation of coagulation also
occurs in this setting.
Since TNF-a appears as an essential mediator of the proco-
agulant activity of OKT3, the irreversible thrombotic compli-
cations induced by prophylactic OKT3 could possibly be pre-
vented by neutralization of TNF-a or abrogation of its release.
This might represent the rationale for a trial of anti-TNF-a
MoAb in patients receiving OKT3 as well as for the clinical
development of non-activating OKT3-like MoAb [14].
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Note added in proof
Since the submission of this manuscript, another study has demon-
strated activation of coagulation and fibrinolysis following OKT3 ad-
ministration IRAASVELD MH, HACK CE, TEN BERGE Ii: Thromb
Haemostas (in press)].
Fig. 6. Role of TNF-a in the generation of
thrombin at the HUVEC surface. HUVEC
were cultured with a supernatant of OKT3-
stimulated PBMC in the presence of various
concentrations of chimeric anti-TNF-a MoAb
or of an isotype-matched control MoAb, and
the generation of thrombin (mean SEM of
triplicate wells) was measured after 4 hours.
Appendix. Abbreviations
Fl+2: Prothrombin fragment 1+2
FDP: Fibrin degradation products
HUVEC: Human umbilical vein endothelial cells
MoAb: Monoclonal antibody
PBMC: Peripheral blood mononuclear cells
TN F-a: Tumor necrosis factor-alpha
VWF: von Willebrand factor
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